Mirum Pharmaceuticals, Inc. has entered into an Asset Purchase Agreement with Travere Therapeutics, Inc. to purchase assets related to the development and commercialization of Chenodal and Cholbam for up to $445 million in cash, with certain milestones to be achieved.